Clinical Trials Logo

Clinical Trial Summary

Adjuvant hormone treatments for early breast cancer are associated with frequent bothersome side effects with major negative impact on patients' quality of life and treatment adherence. Patients most commonly report menopausal symptoms including vaginal dryness, vaginal bleeding, and dyspareunia. Even though previous studies have reported that estrogen topical agent relives these symptoms, non-hormonal therapy should be considered first due to concerns about the role of estrogen in breast cancer development. Therefore, this trial is planned to evaluate the efficacy and safety of LacuD (hyaluronic acid, lactic acid and alginate) in the vaginal environment of breast cancer patients receiving hormone therapy.


Clinical Trial Description

- Registered subjects are 1:1 randomized using a random sequencing generator (www.random.org). Experimental group with 30 patients and Control group with 30 patinets. - In the case of the experimental group, LACUDY 2mL is inserted twice a week for a month before going to bed for 4 weeks. - Unpack the product and take it out. - Remove the cap by turning it. - Fit the nozzle to the end of the syringe and turn it to combine. - Hold the syringe with the nozzle facing the vulva, insert it about 5-6 cm into the vagina, and then slowly press the tip of the push rod with patient's thumb to inject all the liquid in the syringe into the vagina. - Slowly remove the syringe as the nozzle opens. - It is recommended to wear a pad as the injected solution may flow out. - In the case of the control group, they go about their daily lives without any treatment. - Both the experimental group and the control group are instructed not to administer intravaginal suppositories or other drugs related to vaginal atrophy and sexual function improvement. - A total of 2 questionnaires were conducted before and after treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05651087
Study type Interventional
Source Kyungpook National University Chilgok Hospital
Contact
Status Not yet recruiting
Phase N/A
Start date December 20, 2022
Completion date February 28, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05766410 - A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC Phase 2
Recruiting NCT05467891 - Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer Phase 2
Active, not recruiting NCT04997941 - Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients Phase 2
Recruiting NCT05452213 - Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients Phase 4
Active, not recruiting NCT05064085 - Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer Phase 1
Recruiting NCT05501704 - ETHAN - ET for Male BC Phase 2
Not yet recruiting NCT05122377 - RWE About QOL and Compliance of Patients With OFS in China
Not yet recruiting NCT04891731 - Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
Terminated NCT04942054 - A Study in Patients With Advanced Breast Cancer Phase 1
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Suspended NCT05503108 - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Phase 3
Recruiting NCT04925284 - Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Phase 1
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Completed NCT01177397 - Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT05165225 - Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial Phase 2
Recruiting NCT05573126 - Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer Phase 1/Phase 2
Recruiting NCT05608252 - VS-6766+Abema+Fulv in Met HR+/HER- BC Phase 1/Phase 2
Recruiting NCT05868226 - PRE-I-SPY Phase I/Ib Oncology Platform Program Phase 1
Recruiting NCT05115474 - Study of Screening Brain MRIs in Stage IV Breast Cancer
Recruiting NCT05524584 - Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer Phase 2